Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arena Pharmaceuticals (NQ: ARNA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 10, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 99.87 (1)
Ask (Size) 100.00 (88)
Prev. Close 99.98
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 61,074,416
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets

Performance

More News

Read More
Arena Pharmaceuticals Inc. Climbs To Annual-High Share Price
Via Benzinga
Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price
Via Investor Brand Network
Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price
Via Investor Brand Network
7 Biotech Stocks With Key Catalysts in March
Via InvestorPlace
Expert Ratings For Arena Pharmaceuticals
Via Benzinga
Bullish Tuesday For Marijuana Stocks - Nine Energy Service, ReneSola Among Top Gainers
Via Benzinga
Futures Rebound On "Massive" EU Bond Stimulus Plan; Nickel Halted After Record Surge, Gold Over $2000
Via Talk Markets
Pfizer's Cannabinoid-Related Biotech Company Arena's Q4 Net Loss Grows 27% YoY
Via Benzinga
Arena Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates
From Arena Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Via Benzinga
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23
From Arena Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022
Via Benzinga
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
7 Long-Term Stocks to Buy and Hold Until 2030
Via InvestorPlace
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
10 Biggest Price Target Changes For Tuesday
Via Benzinga
Benzinga's Bulls And Bears Of The Past Week: Pfizer, Bank Of America, Beyond Meat, GameStop, AMC, Overstock And More
Via Benzinga
The Week In Cannabis: Pfizer, Visa, $730M+ In Financings, Malta, EU, Columbia Care, MedMen, Uruguay And More
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2021
Via Benzinga
What 6 Analyst Ratings Have To Say About Arena Pharmaceuticals
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.